• If you are wondering whether Recursion Pharmaceuticals, at a last close of US$3.51, is a bargain or a value trap, this article walks through what the current price really implies.
• The stock has been volatile, with a 10.7% gain over the last 30 days, returns of 16.4% year to date, and 38.7% over the past year. This raises questions about how the market is reassessing its prospects and risks.
• Recent coverage has focused on how Recursion Pharmaceuticals fits within the broader biotech space and what that means for investors trying to make sense of its share price. This context is important because sentiment around the sector can influence valuation as much as company specific developments.
• Right now, Recursion Pharmaceuticals has a valuation score of 2 out of 6. The next sections break down what different valuation approaches say about the stock and point to a more complete way to think about value that comes at the end of this article.

Recursion Pharmaceuticals scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Recursion Pharmaceuticals Discounted Cash Flow (DCF) Analysis

The DCF model estimates what a company could be worth by projecting its future cash flows and discounting them back to today, so you can compare that value to the current share price.

For Recursion Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections in $. The latest twelve month free cash flow shows an outflow of about $387.8 million. Analyst inputs feed into the earlier years, then Simply Wall St extrapolates further out, with projected free cash flow reaching $176.0 million by 2030.

Across the 10 year projection window, discounted free cash flows range from outflows of around $16.3 million and $74.8 million in 2026 and 2027 to inflows above $100 million a year in the later period. When these are added together and adjusted for the second stage of the model, the estimated intrinsic value comes out at US$9.27 per share.

Against a recent share price of US$3.51, this implies the stock trades at a 62.1% discount to the DCF estimate, so the model indicates Recursion Pharmaceuticals as undervalued on these assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Recursion Pharmaceuticals is undervalued by 62.1%. Track this in your watchlist or portfolio, or discover 56 more high quality undervalued stocks.

Approach 2: Recursion Pharmaceuticals Price vs Sales

Price based multiples are often used for profitable companies because they connect what you pay per share to what the business is currently generating in earnings, sales or book value. For high growth or higher risk names, investors usually accept a higher P/E, P/S or P/B ratio, while slower growth or riskier profiles tend to justify lower multiples.

For Recursion Pharmaceuticals, the preferred metric is the P/S ratio. The stock is trading on a P/S of 24.83x, compared with the Biotechs industry average of 11.09x and a peer average of 15.48x. On these simple comparisons, the shares sit at a higher multiple than both the broader industry and peers.

Simply Wall St also uses a proprietary “Fair Ratio”, which estimates what the preferred multiple could be once factors such as earnings growth, profit margins, industry, market cap and company specific risks are considered. This Fair Ratio is 0.00x for Recursion Pharmaceuticals, which is much lower than the current 24.83x P/S. On this basis, the shares screen as expensive relative to the level that Fair Ratio implies.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Recursion Pharmaceuticals Narrative

Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St give you a clear story behind the numbers by linking your view of Recursion Pharmaceuticals to specific assumptions for future revenue, earnings and margins. This is then turned into a Fair Value you can compare with the current price to help you decide whether the stock looks attractively priced or stretched. Each Narrative lives on the Community page and updates automatically as fresh news or earnings arrive. One investor might build a cautious Recursion view with a Fair Value near US$1.97 that focuses on insider selling and a tough track record. Another might lean into an optimistic Recursion story with a Fair Value around US$11.00 based on AI driven drug discovery, cash runway and partnership milestones. Both perspectives coexist in a simple, accessible format you can review and stress test against your own expectations.

For Recursion Pharmaceuticals however, we will make it really easy for you with previews of two leading Recursion Pharmaceuticals Narratives:

Fair Value: US$8.38

Implied discount to this Fair Value: about 58% based on the last close of US$3.51.

Revenue growth input used in this view: 94%.

• Frames Recursion as moving from a high concept AI drug discovery story to a business with clinical data, material partner payments and a cash runway described as extending through 2027.
• Highlights partnership inflows reported at over US$500 million and milestone payments from Roche as support for the platform generating revenue, not just costs.
• Points to a large cash balance and leadership changes as reasons this author sees the company as well funded with a focus on turning its pipeline into commercial products.

Fair Value: US$1.97

Implied premium to this Fair Value: about 78% based on the last close of US$3.51.

Revenue growth input used in this view: 52.84%.

• Argues that insider selling is a key concern and sees this as a sign that management does not back the equity story.
• Focuses on the share price path from above US$40 to below US$4 as evidence that prior optimism has not translated into outcomes for shareholders.
• Emphasises the absence of approved drugs so far and uses this to label the stock as high risk despite the potential described by other investors.

These two Narratives sit side by side with three bullish and two bearish views in total, so you can weigh a wide range of assumptions before forming your own stance on Recursion Pharmaceuticals.

Do you think there's more to the story for Recursion Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.